Metabolic & Cardiometabolic
arabinoxylan dietary fiber decreases LDL cholesterol
In plain terms: Does the wheat fiber arabinoxylan actually lower LDL cholesterol?
Arabinoxylan does modestly lower LDL in small trials via bile-acid loss, but calling it the single "most effective" fiber overstates the evidence versus beta-glucan and psyllium.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
A small purified-fibre crossover in eighteen people found arabinoxylan cutting LDL and raising bile-acid excretion, which is a coherent mechanism. Most other trials did not reproduce it: concentrated arabinoxylan improved postprandial glucose without changing lipids, and a 15-gram daily dose moved glucose and triglycerides but not LDL significantly.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ho, Sievenpiper, Zurbau, Blanco Mejia, Jovanovski, Au-Yeung, Jenkins, Vuksan 2016 · Br J Nutr | meta-analysis | supports | high | The pooled exposure is oat beta-glucan alone — 'only RCT that investigated the effects of supplementing β-glucan from oat products on LDL-cholesterol, non-HDL-cholesterol and/or apoB were included in the analysis' — and the word 'arabinoxylan' does not occur anywhere in the article. The prior extract's 'arabinoxylan-class' label was an interpolation, not the paper's: beta-glucan is a mixed-linkage (1->3)(1->4)-beta-D-glucan, chemically distinct from arabinoxylan's arabinose-substituted xylan backbone, and where wheat/rye material appears in this literature it sits on the CONTROL side of the included trials. What the paper does show, for the beta-glucan claim rather than this one: 'In total, fifty-eight trials (n 3974) were included' and 'A median dose of 3·5 g/d of oat β-glucan significantly lowered LDL-cholesterol (−0·19; 95 % CI −0·23, −0·14 mmol/l, P<0·00001), non-HDL-cholesterol (−0·20; 95 % CI −0·26, −0·15 mmol/l, P<0·00001) and apoB (−0·03; 95 % CI −0·05, −0·02 g/l, P<0·0001) compared with control interventions.' |
| Lu ZX, Walker KZ, Muir JG, Mascara T, O'Dea K 2000 · Am J Clin Nutr | RCT | mixed | moderate | Wheat arabinoxylan reduced postprandial glucose in normoglycemic subjects; lipid/LDL effects not established in this acute study. |
| Hartvigsen ML, Gregersen S, Lærke HN, Holst JJ, Bach Knudsen KE, Hermansen K 2014 · Eur J Clin Nutr | RCT | tested-null | moderate | Concentrated arabinoxylan improved postprandial glucose/appetite in metabolic syndrome but did not demonstrate meaningful LDL lowering. |
| Garcia AL, Steiniger J, Reich SC, Weickert MO, Harsch I, Machowetz A, Mohlig M, Spranger J, Rudovich NN, Meuser F, Doerfer J, Katz N, Speth M, Zunft HJ, Pfeiffer AH, Koebnick C 2006 · Br J Nutr | RCT | mixed | moderate | 15g/day arabinoxylan lowered fasting glucose, triglycerides and apoA-1 but showed no significant effect on apoB or LDL-related fractions. |
| Lancaster SM, Lee-McMullen B, Abbott CW, Quijada JV, Hornburg D, Park H, Perelman D, Peterson DJ, Tang M, Robinson A, Ahadi S, Contrepois K, Hung CJ, Ashland M, McLaughlin T, Boonyanit A, Horning A, Sonnenburg JL, Snyder MP 2022 · Cell Host Microbe | RCT | supports | moderate | n=18 crossover purified-fiber feeding: arabinoxylan significantly cut LDL & raised bile acids; the exact paper Norwitz cites, small n. |
| Whitehead A, Beck EJ, Tosh S, Wolever TMS 2014 · Am J Clin Nutr | meta-analysis | tested-null | high | The measured exposure is 'Oat β-glucan (OBG)' and nothing else: 'A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control.' The string 'arabinoxylan' occurs zero times in the full text, Table 1, or Supplemental Tables 1-4. Worse for the inference, wheat bran and wheat fibre - arabinoxylan's food matrix - are on the CONTROL side of ten of the 28 included trials, thirteen comparison rows (Anderson, Donazzolo, Uusitupa, Wolever 4L/3M/4M/3H, Abrahamsson, Kestin vs wheat bran; Kabir, Kerckhoffs, Theuwissen, Whyte vs wheat fibre), chosen precisely as low-viscous-fibre comparators. The prior extracted was an explicit mechanistic-class extrapolation - 'the mechanistic class to which wheat arabinoxylan belongs' - not a measurement, and it asserted a lowering effect while the note recorded stance tested-null, so it was internally inconsistent as well as off-scope. What the paper does establish for the beta-glucan arm: 'of −0.25 mmol/L (95% CI: −0.30, −0.20' on LDL. Nothing here weighs on arabinoxylan in either direction. |
| Schioldan AG, Gregersen S, Hald S, Bjørnshave A, Bohl M, Hartmann B, Holst JJ, Stødkilde-Jørgensen H, Hermansen K 2018 · Eur J Nutr | RCT | mixed | moderate | 4-wk arabinoxylan+resistant-starch diet in metabolic syndrome improved postprandial metabolism but did not significantly lower fasting LDL vs refined-carb. |
| Lu ZX, Walker KZ, Muir JG, O'Dea K 2004 · Diabetologia/Eur J Clin Nutr | RCT | mixed | low | Arabinoxylan-rich wheat fiber improved glycaemic control in T2D; lipid/LDL benefit not the primary or robust finding. |
| Hall KD, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen KY, Chung ST, Costa E, Courville A, Darcey V, Fletcher LA, Forde CG, Gharib AM, Guo J, Howard R, Joseph PV, McGehee S, Ouwerkerk R, Raisinger K, Rozga I, Stagliano M, Walter M, Walter PJ, Yang S, Zhou M 2019 · Cell Metab | RCT | tested-null | moderate | Context disconfirmer: fiber alone is one lever; whole-diet trials show LDL driven by many factors, AX not uniquely dominant. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.